Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
Recent Research Progress
Blood vessel epicardial substance (BVES) is a tight junction-associated protein that was originally found in cDNA screening of developing hearts. Studies over the past few years have revealed that not only BVES is expressed in heart and bone tissue, but also that BVES is also expressed throughout the gastrointestinal epithelium. Mice lacking BVES maintain more severe intestinal damage and inflammation. Furthermore, BVES is inhibited in gastrointestinal cancer, and mouse models show that loss of BVES promotes tumor formation. Recent studies from multiple laboratories have shown that BVES can regulate several molecular pathways, including cyclic adenosine monophosphate (cAMP), WNT, and promote the degradation of the oncogene c-Myc.
The absence of BVES promotes CAC
BVES mRNA is reduced by hypermethylation of the promoter in tumors from colitis-associated cancer (CAC) patients. Importantly, the hypermethylation of the BVES promoter is concurrently present in the distant non-malignant appearance mucosa. As seen in human patients, BVES are under-expressed in experimental inflammatory carcinogenesis, and BVES-/- mice have increased tumor diversity and dysplasia after azoxymethane (AOM)/ dextran sodium sulfate (DSS) administration. Molecular analysis of BVES-/- tumors showed elevated Wnt activation and c-Myc levels. In terms of mechanism, Bobak Parang et al. identified a novel signaling pathway, namely the interaction of BVES with the protein phosphatase 2A (PP2A) regulatory subunit PR61α, which mediates the destruction of cMyc. In conclusion, deletion of BVES promotes inflammatory tumor genesis through Wnt signaling and dysregulation of the oncogene c-Myc (Figure 1). The BVES promoter methylation status can be used as a CAC biomarker.
Figure 1. Working model of the role of BVES in regulating c-Myc degradation and CAC development (Parang Bobak, et al. GUT, 2017)
BVES inhibition triggers human hepatocellular carcinoma EMT
Metastasis contributes to a poor prognosis of hepatocellular carcinoma (HCC). However, the mechanism by which primary HCC cells develop into a metastatic phenotype remains unclear. Recently, investigations have shown that BVES was down-regulated in human liver cancer tissues and HCC cell lines with high metastatic potential. Ping Han et al. selected Huh7 cells (BVES high-level expressing cells) to study the role of BVES in HCC. After BVES inhibition, Huh7 cells exhibited some morphological changes, including cytoskeletal rearrangement and ligation disruption. Cell migration and invasion were increased concomitant with increased expression of vimentin, IL-6, MMP2, MMP9 and decreased expression of E-cadherin. Finally, the expression of the epithelial-mesenchymal transition (EMT) transcription factors Snail1 and Twist1 was significantly increased in BVES knockdown cells. These findings suggest that down-regulation of BVES in HCC induces EMT, thereby promoting invasion and metastasis of HCC cells.
BVES may be a potential target for enhancing heart protection
BVES play a role in muscle regeneration, heart rate regulation, hypoxia tolerance, and ischemic preconditioning. Expression of BVES is elevated in cardiomyocytes maintained in serum-free defined medium. BVES deficiency caused by small interfering RNA (siRNA)-mediated gene silencing leads to myocardial cell injury and death, up-regulation of pro-apoptotic protein Bcl-2/adenovirus E1B 19-kDa interacting protein 3 (Bnip3), as well as reduction in Rac1-GTPase activity and in Akt phosphorylation. Binding to BVES and Bnip3 silencing attenuated cell damage and prevented up-regulation of Bnip3 induced by BVES silencing alone. Chromatin immunoprecipitation indicated increased binding of the transcription factor FoxO3 to the Bnip3 promoter, although augmentation of FoxO3 in the nuclei was not detected. In contrast, the transcription factor NF-kB was excluded from the nucleus of BVES -deficient cardiomyocytes and exhibited reduced binding to the Bnip3 promoter. The data suggests that BVES regulates Bnip3 expression by altering Rac1 activity and FoxO3 and NF-kB transcription factors, maintaining cardiomyocyte viability in the absence of serum, pointing to BVES as a potential target for enhanced cardioprotection.
In conclusion, BVES regulates a variety of intracellular signaling pathways and is closely related to a variety of disease mechanisms. Although recent studies have elucidated the in vivo function of BVES, it remains to be seen how BVES plays a role in other tissues such as the lungs or breast. The production of tissue-specific BVES knockout mice will be the key to revealing its function.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.